文献速递浆细胞疾病

鲁索替尼联合甲泼尼龙治疗复发/难治性多发性骨髓瘤患者

Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.
PubMed 文献 · Br J Haematol · 2022-12-09

这项研究评估口服鲁索替尼(15 mg 每日两次)联合口服甲泼尼龙(40 mg 隔日一次)治疗既往接受过蛋白酶体抑制剂、来那度胺、糖皮质激素及三种以上方案的进展期多发性骨髓瘤患者,计划入组29例全部完成入组,随访至2022年4月28日。总缓解率为31%,中位缓解持续时间13.1个月,中位无进展生存期3.4个月,治疗总体耐受良好。

要点

  • 鲁索替尼联合甲泼尼龙在既往重度治疗的多发性骨髓瘤患者中总缓解率为31%。
  • 中位缓解持续时间13.1个月,中位无进展生存期3.4个月。
  • 高危细胞遗传学患者中亦观察到缓解,治疗总体耐受良好。

核心结论

  • 鲁索替尼联合甲泼尼龙在既往重度治疗的多发性骨髓瘤患者中显示出显著临床活性,且高危细胞遗传学患者中亦获得缓解。
  • 这是首个显示JAK抑制剂联合类固醇在多发性骨髓瘤患者中有活性的临床研究,扩展了这些药物在骨髓增殖性肿瘤以外癌症中的潜在用途。

研究设计与样本

  • 研究评估口服鲁索替尼(15 mg 每日两次)联合口服甲泼尼龙(40 mg 隔日一次)治疗进展期多发性骨髓瘤患者。
  • 入组患者既往接受过蛋白酶体抑制剂、来那度胺、糖皮质激素及三种以上方案。
  • 计划入组29例患者全部完成入组,随访至2022年4月28日。
  • 既往治疗中位线数为6(范围3-12)。
  • 28例患者可评估细胞遗传学和荧光原位杂交,分别有9例(32%)和17例(70%)患者显示高危细胞遗传学和/或1q+。

主要发现

  • 总缓解率为31%。
  • 中位缓解持续时间为13.1(范围2.8-22.0)个月。
  • 中位无进展生存期为3.4(范围0.5-24.6)个月。
  • 治疗总体耐受良好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although Janus kinase (JAK) inhibitors have demonstrated efficacy for treating autoimmune disorders and myeloproliferative neoplasms, their efficacy in treating other types of cancer has not been clearly demonstrated. We evaluated oral ruxolitinib (15 mg twice daily) with oral methylprednisolone (40 mg every other day) for multiple myeloma (MM) patients with progressive disease who had received a proteasome inhibitor, lenalidomide, glucocorticosteroids and three or more prior regimens. All of the planned 29 patients had been enrolled with follow-up until 28 April 2022. Median lines of prior therapy were 6 (range 3-12). Cytogenetics and fluorescent in situ hybridization were evaluable in 28 patients; 9 (32%) and 17 (70%) patients showed high-risk cytogenetics and/or 1q+, respectively. The overall response rate was 31%. The median duration of response was 13.1 (range 2.8-22.0) months. Median progression-free survival rate was 3.4 (range 0.5-24.6) months, Overall, the treatment was well tolerated. The combination of ruxolitinib and methylprednisolone demonstrated significant clinical activity among previously heavily-treated MM patients, and responses were achieved among patients who had high-risk cytogenetics. This is the first clinical study to show activity of JAK inhibitors in combination with steroids for MM patients and expands the potential use of these drugs to those with cancers other than myeloproliferative neoplasms.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Berenson JR, Martinez D, Safaie T, et al. Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma. Br J Haematol. 2022. PMID: 36482815. doi:10.1111/bjh.18593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。